secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0001193125-22-250165
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helsinn terminates oncology collaboration for infigratinib; BridgeBio continues non-oncology development
--------------------------------------------------------------------------------

- QED Therapeutics, BridgeBio subsidiary, received termination notice from Helsinn for infigratinib oncology license agreement.
- Helsinn cites commercial considerations for termination of February 2022 agreement.
- BridgeBio to continue development of infigratinib for achondroplasia worldwide excluding China, Hong Kong, Macau.
- Termination affects commercialization rights for oncology indications worldwide ex-China, Hong Kong, Macau.
- No financial terms disclosed; impact on future revenues uncertain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522250165/0001193125-22-250165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000119312522250165/d283481d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-250165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer